Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma

Michael F. Sharpnack, Nilini Ranbaduge, Arunima Srivastava, Ferdinando Cerciello, Simona G. Codreanu, Daniel C. Liebler, Celine Mascaux, Wayne O. Miles, Robert Morris, Jason E. McDermott, James L. Sharpnack, Joseph Amann, Christopher A. Maher, Raghu Machiraju, Vicki H. Wysocki, Ramaswami Govindan, Parag Mallick, Kevin R. Coombes, Kun Huang, David P. Carbone

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Introduction: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting. Methods: RNA sequencing and liquid chromatography/liquid chromatography–mass spectrometry proteomics data were generated from 51 surgically resected non–small cell lung tumors with known recurrence status. Results: We present a rationale and framework for the incorporation of high-content RNA and protein measurements into integrative biomarkers and show the potential of this approach for predicting risk of recurrence in a group of lung adenocarcinomas. In addition, we characterize the relationship between mRNA and protein measurements in lung adenocarcinoma and show that it is outcome specific. Conclusions: Our results suggest that mRNA and protein data possess independent biological and clinical importance, which can be leveraged to create higher-powered expression biomarkers.

Original languageEnglish
Pages (from-to)1519-1529
Number of pages11
JournalJournal of Thoracic Oncology
Issue number10
StatePublished - Oct 2018


  • Biomarkers
  • Lung adenocarcinoma
  • Proteogenomics
  • Proteomics


Dive into the research topics of 'Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma'. Together they form a unique fingerprint.

Cite this